Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro

Filtros
- Dermatitis Atópica
- General

Ponowne rozważenie wpływu kontroli glikemii na ryzyko chorób sercowo-naczyniowych w cukrzycy typu 2: Ewaluacja XXI wieku

제1형 당뇨병 성인 환자의 자발적 운동 세션에서 Insulin Glargine 300 U/ml 또는 Insulin Degludec 100 U/ml 투여 결과를 비교한 무작위 배정, 교차 시험(ULTRAFLEXI-1 Study)

Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)
^{Moser O et al. Diabetes Technol Ther. 2023;25(3):161-168.}

Hypertension as a Modifiable Risk Factor: A New Perspective on Cardiovascular and Renal Protection

Hypertension as a Modifiable Risk Factor: A New Perspective on Cardiovascular and Renal Protection

Glycaemic control in a cardiovascular benefit world by Dr. Aslam Amod

A talk by Dr. Aslam Amod about how to achieve glycaemic control with cardiovascular benefit having a recent uptake in the diabetes landscape.

Diabetes and CKD: What does the Diabetologist need to know in 2023 by Dr. Hoosen Randeree

A talk by Dr. Hoosen Randeree on what a Diabetologist needs to know on diabetes and chronic kidney disease.

Simplifying management of type 2 diabetes by Dr. Gracjan Podgorski

A talk by Dr. Gracjan Podgorski about how to simplify the management of patients living with T2DM.

Diabetes and aging: from treatment goals to pharmacological therapy by Dr. Reyna Daya

A talk by Dr. Reyna Daya on the relationship between diabetes and aging, highlighting the treatment goals and pharmacological therapy for the elderly patient.

Type 1 diabetes and exercise by Professor Othmar Moser

An educational video exploring exercise in individuals with type 1 & ULTRAFLEXI-1 study.

Glargine U300: From clinical trials into practice - Dr. Jay Narainsamy

A video talk about the use of Glargine U300 in clinical practice.

The InRange trial results - Professor Tadej Battelino

The InRange trial results interview with Professor Tadej Battelino.

Exercise and Diabetes Management by Rory McCrimmon

A video about the challenges that Type 1 Diabetes patients face when exercising.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

MAT-CO-2400825 V1.0 03/2024

Page menu

Áreas terapeúticas

Patología

Filtros

Ponowne rozważenie wpływu kontroli glikemii na ryzyko chorób sercowo-naczyniowych w cukrzycy typu 2: Ewaluacja XXI wieku

제1형 당뇨병 성인 환자의 자발적 운동 세션에서 Insulin Glargine 300 U/ml 또는 Insulin Degludec 100 U/ml 투여 결과를 비교한 무작위 배정, 교차 시험(ULTRAFLEXI-1 Study)

Hypertension as a Modifiable Risk Factor: A New Perspective on Cardiovascular and Renal Protection

Hypertension as a Modifiable Risk Factor: A New Perspective on Cardiovascular and Renal Protection

Glycaemic control in a cardiovascular benefit world by Dr. Aslam Amod

Diabetes and CKD: What does the Diabetologist need to know in 2023 by Dr. Hoosen Randeree

Simplifying management of type 2 diabetes by Dr. Gracjan Podgorski

Diabetes and aging: from treatment goals to pharmacological therapy by Dr. Reyna Daya

Type 1 diabetes and exercise by Professor Othmar Moser

Glargine U300: From clinical trials into practice - Dr. Jay Narainsamy

The InRange trial results - Professor Tadej Battelino

Exercise and Diabetes Management by Rory McCrimmon